Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical, Inc. (LFCR) reports developments as a fully integrated injectables CDMO focused on sterile pharmaceutical products. The company provides development, fill and finish services for syringes, vials and cartridges, including complex formulations, and manufactures injectable-grade hyaluronic acid for biopharmaceutical and biotechnology customers.
Company news commonly covers financial results, revenue and Adjusted EBITDA guidance, commercial site transfer programs, technical transfer and PPQ work, new CDMO manufacturing service agreements, customer program expansions, cost-containment initiatives, biomanufacturing conference participation and Nasdaq inducement equity grants.
Lifecore Biomedical announced it received a notice from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ending November 27, 2022. The company has 60 days from January 11, 2023, to submit a compliance plan, with a potential extension to July 5, 2023, if accepted. The notice does not affect the trading of Lifecore's securities. Lifecore is committed to filing the report promptly to regain compliance.
Lifecore Biomedical has successfully raised $38.75 million through a private placement of Series A convertible preferred stock to enhance its working capital and execute capital expenditures. This move coincides with the company's ongoing divestment of non-CDMO assets. Additionally, Lifecore has amended its credit facilities to boost liquidity by deferring $2.2 million in debt repayments until 2025 and relieving certain financial covenants. The company also appointed Nathaniel Calloway, PhD, and Christopher Kiper to its Board of Directors.
Lifecore Biomedical has announced a successful closing of a $5 million private placement of its common stock at $7.97 per share, with Wynnefield Capital as an investor. The funds will be utilized for capital expenditures to enhance manufacturing capacity, responding to growing demand for complex sterile injectable pharmaceuticals. President James G. Hall noted the ongoing demand for their specialized manufacturing capabilities and emphasized the importance of long-term stockholder support in achieving growth ambitions.
Lifecore Biomedical has officially completed its transition from Landec Corporation, adopting its new name and Nasdaq ticker symbol, LFCR, effective November 15, 2022. This change reflects the company's strategic focus on its contract development and manufacturing organization (CDMO) business, specializing in sterile injectable pharmaceutical products and Hyaluronic Acid. The corporate headquarters has relocated to Chaska, MN, and a new investor relations website has been launched. Leadership remains stable as the company aims for revenue and EBITDA growth.